Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05944965 · ClinicalTrials.gov registry record · Phase 1
Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT05944965 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 27 participants.
The verdict
NCT05944965, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Current therapies available for obstructive sleep apnea (OSA) have varying degrees of efficacy due to the complex nature of the disorder. A reduction in pharyngeal muscle activity characterizes OSA, and recent research has shown that combining atomoxetine and oxybutynin improves OSA severity. Thus this may be a viable treatment option. However, the specific effects of these agents alone and in combination on pharyngeal muscle activity remain unknown. The current study will look at the impact of each drug on pharyngeal muscles to gain insight into the mechanisms of this combination.
Interventions
- DRUG Placebo
- DRUG Atomoxetine 80 MG
- DRUG Atomoxetine 80 mg plus Oxybutynin 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2025-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05944965
The ClinicalTrials.gov registry entry for NCT05944965 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05944965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05944965 about?
NCT05944965 is a clinical study titled "Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea". Current therapies available for obstructive sleep apnea (OSA) have varying degrees of efficacy due to the complex nature of the disorder. A reduction in pharyngeal muscle activity characterizes OSA, and recent research has shown that combining atomoxetine and oxybutynin improves OSA severity. Thus t...
What is the current status of trial NCT05944965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2023-12-01. Estimated completion is 2025-06-17.
What interventions are being tested in trial NCT05944965?
The interventions under investigation include: Placebo (DRUG), Atomoxetine 80 MG (DRUG), Atomoxetine 80 mg plus Oxybutynin 5 mg (DRUG).
Who is sponsoring clinical trial NCT05944965?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.